| |
FULL-TEXT ARTICLE
Prevalence and correlates of persistent intracellular HIV
transcription in individuals on efavirenz versus
atazanavir-based regimens: A prospective cohort study.
Pilalas D, Skoura L, Margariti A,
et al
PLoS One. 2018 Mar
13;13(3):e0194262.
Peper
Prediction of plasma efavirenz concentrations among HIV-positive patients
taking efavirenz-containing combination antiretroviral therapy.
Huang SH, Lin SW, Chang SY,
et al;
Sci Rep. 2017 Nov
23;7(1):16187.
Abstract
In vivo genotoxicity evaluation of efavirenz (EFV) and tenofovir disoproxil
fumarate (TDF) alone and in their clinical combinations in Drosophila
melanogaster.
de Moraes Filho AV, de Jesus Silva Carvalho C,
Mutat Res. 2017
Aug;820:31-38.
5
Abstract
Population approach to efavirenz therapy.
Duarte H, Cruz JP, Aniceto N, et al
J Pharm Sci. 2017 Jun 13.
Abstract
Late efavirenz-induced ataxia and encephalopathy: a case series.
Variava E, Sigauke FR, Norman J, et al
J Acquir Immune Defic Syndr.
2017 May 17.
Abstract
First results of a phase II trial to assess the efficacy of efavirenz in
patients with metastatic androgen-independent prostate cancer.
Houede N, Pulido M, Mourey L, et al
J Clin Oncol. 2012 Feb 10;30(5_suppl):251
Abstract
HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz
Reduces Neural Stem Cell Proliferation In Vitro and In Vivo.
Jin J, Grimmig B, Izzo J, Brown LA,
et al
Cell Transplant. 2016
Nov;25(11):1967-1977.
Abstract
Alkynyl Cinchona Catalysts affect Enantioselective Trifluoromethylation for
Efavirenz under Metal-Free Conditions.
Okusu S, Hirano K, Yasuda Y, et al
Org Lett. 2016 Oct 14.
Abstract
Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the
Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.
Arend C, Rother A, Stolte S, Dringen R.
Neurochem Res. 2016 Sep 21
Abstract
Inhibition of CYP2B6 Activity by Voriconazole Profiled Using Efavirenz
Disposition in Healthy Volunteers.
Desta Z, Metzger IF, Thong N,
Antimicrob Agents Chemother.
2016 Sep 6.
Abstract
Efavirenz biotransformation as an UP-STREAM EVENT of mood changes in
HIV-infected patients.
Grilo NM, Correia MJ, Sequeira C,
Toxicol Lett. 2016 Aug 16.
Abstract
Engineered nanoparticles of Efavirenz using methacrylate co-polymer
(Eudragit-E100) and its biological effects in-vivo.
Hari BN, Narayanan N, Dhevendaran K, Ramyadevi D.
Mater Sci Eng C Mater Biol Appl. 2016 Oct 1;67:522-32
Abstract
FULL-TEXT ARTICLE
Cholesterol Hydroxylase CYP46A1: Mapping of the Allosteric Site for
Efavirenz, a Drug that Stimulates Enzyme Activity.
Anderson KW, Mast N, Hudgens JW,
et al
J Biol Chem. 2016 Apr
7.
Peper
Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication
for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral
Therapy (HAART) in Resource-Limited Settings.
Thomford NE,
Awortwe C, Dzobo K,
et al
Molecules. 2016 Feb 16;21(2). pii:
E211.
Abstract
Efavirenz a nonnucleoside reverse transcriptase inhibitor of
first-generation: Approaches based on its medicinal chemistry.
Bastos MM, Costa
CC, Bezerra TC, et al
Eur J Med Chem. 2016 Jan 27;
Abstract
A combined TD-DFT and spectroscopic investigation of the
solute-solvent interactions of efavirenz.
Jordaan MA, Singh P, Martincigh BS.
Spectrochim Acta A Mol Biomol Spectrosc.
2015 Dec 8;157:204-210.
Abstract
Efavirenz Induced Suicidal Death of Human Erythrocytes.
Bissinger R, Bouguerra G, Al Mamun Bhuyan A,
Cell Physiol Biochem. 2015;37(6):2496-507
Abstract
Efavirenz a nonnucleoside reverse transcriptase inhibitor of
first-generation: Approaches based on its medicinal chemistry.
Bastos MM, Costa CC, Bezerra TC, et al
Eur J
Med Chem. 2015 Nov 25;108:455-465.
Abstract
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase
II Metabolites of Efavirenz in Plasma, Urine and Cerebro-Spinal Fluid.
Aouri M, Barcelo C, Ternon B,
et al
Drug Metab Dispos.
2015 Nov 9
Abstract
FULL-TEXT ARTICLE
A Randomized Comparison of Anthropomorphic Changes With Preferred and
Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational
Settings.
Erlandson KM, Taejaroenkul S, Smeaton L, et al
Open Forum Infect Dis. 2015
Jun 24;2(3):ofv095.
Peper |
Lipid-based nutrient supplements do not affect efavirenz but lower plasma
nevirapine concentrations in Ethiopian adult HIV patients.
Abdissa A,
Olsen MF, Yilma D, et al
HIV Med. 2015 May 13.
Abstract
Plasma concentrations of efavirenz, darunavir/ritonavir and
raltegravir in HIV-HCV-coinfected patients without liver cirrhosis
in comparison with HIV-monoinfected patients.
Calza L, Danese I, Colangeli V, et al
Infect Dis (Lond). 2015 Apr 15:1-12.
Abstract
Correlation between microstructure and bioequivalence in Anti-HIV Drug
Efavirenz.
Fandaruff C, Segatto Silva MA, et al
Eur J Pharm Biopharm. 2015
Feb 3.
Abstract
Molecularly imprinted nanoparticles prepared by miniemulsion polymerization as a
sorbent for selective extraction and purification of efavirenz from human serum
and urine.
Pourfarzib M, Shekarchi M, Rastegar H, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2015 Jan 1;974:1-8.
Abstract
Protein-free Efavirenz is Equivalent in Cerebrospinal Fluid &
Blood Plasma: Applying the Law of Mass Action to Predict Protein-Free Drug
Concentration
Avery LB, Sacktor N, McArthur JC,
Hendrix CW.
Antimicrob Agents Chemother. 2013 Jan 7.
Abstract
Substantial effect of efavirenz monotherapy on bilirubin levels in
healthy volunteers.
Metzger IF, Quigg TC, Epstein N, et al
Curr
Ther Res Clin Exp. 2014
Sep 27;76:64-9.
Abstract
Efavirenz Induces Neuronal Autophagy and Mitochondrial
Alterations.
Purnell PR, Fox HS.
J Pharmacol Exp Ther.
2014 Aug 26.
Abstract
Differential Subcutaneous Adipose Tissue Gene Expression Pattern with
Efavirenz or Lopinavir/ritonavir in Antiretroviral-Naďve Patients: A
Randomized Clinical Trial.
Egańa-Gorrońo L, Martínez E, Domingo P, et al
Antimicrob Agents Chemother.
2014 Aug 25
Abstract
FULL-TEXT ARTICLE
Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents
That Concern Prescribers and Patients:
A
Feasibility Study and Call for a Trial.
Achhra AC, Boyd MA, Law MG, et al
PLoS One. 2014 Jun
26;9(6):e99530.
Paper
FULL-TEXT ARTICLE
Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative
Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated
Neurocognitive Disorders (HAND).
Brown LA, Jin J, Ferrell D, et al
PLoS One. 2014 Apr 23;9(4):e95500.
Paper
Has the time come to abandon efavirenz for first-line antiretroviral therapy?
Raffi F, Pozniak AL, Wainberg MA.
J Antimicrob Chemother. 2014 Mar 5.
Abstract
The phenolic metabolites of the anti-HIV drug efavirenz: Evidence for distinct
reactivities upon oxidation with Frémy's salt.
Harjivan SG, Wanke R, Ferreira da Silva JL, et al
Eur J Med Chem. 2013
Dec 31;74C:7-11
Abstract
Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in
poly(epsilon-caprolactone) nanoparticles by a spray-drying method.
Tshweu L, Katata L, Kalombo L, Chiappetta DA,
et al
Nanomedicine (Lond).
2013 Dec 23
Abstract
Low level of efavirenz in HIV-1-infected Thai adults is
associated with the CYP2B6 polymorphism.
Sukasem C, Manosuthi W, Koomdee
N, et al
Infection. 2013 Nov
30.
Abstract
Factors associated with remaining on initial randomized
efavirenz-containing regimens.
Smurzynski M, Wu K, Schouten JT, et al
AIDS.
2013 Jul 31;27(12):1887-97.
Abstract
Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma
are equivalent: applying the law of mass action to predict protein-free drug
concentration.
Avery LB, Sacktor N, McArthur JC, Hendrix CW.
Antimicrob Agents Chemother.
2013 Aug;57(8):4095
Abstract |
Basis for the Early and Preferential Selection of the E138K
Substitution in HIV-1 Reverse Transcriptase with Etravirine.
McCallum M, Oliveira M, Ibanescu RI,
et al
Antimicrob Agents Chemother. 2013 Jul 15
Abstract
Efavirenz Stimulates HIV-1 Reverse Transcriptase RNase H Activity by a
Mechanism Involving Increased Substrate Binding and Secondary Cleavage
Activity.
Muchiri JM, Li D, Dykes C, Bambara RA.
Biochemistry. 2013 Jun 27
Abstract
The HIV antiretroviral drug efavirenz has LSD-like properties.
Gatch MB, González Maeso J,
Huang RQ, et al
Neuropsychopharmacology.
2013 May 24.
Abstract
Cytotoxic effect of Efavirenz is selective against cancer cells
and associated with the cannabinoid system.
Hecht M, Harrer T, Büttner M, et
al
AIDS.
2013 Apr 22.
Abstract |
FULL-TEXT ARTICLE
Kinetics of Microbial Translocation Markers in Patients on Efavirenz or
Lopinavir/r Based Antiretroviral Therapy.
Vesterbacka J, Nowak P, Barqasho B, . et al
PLoS One. 2013;8(1):e55038.
Paper |
Efavirenz enhances HIV-1 Gag processing at the plasma membrane through Gag-Pol
dimerization.
Sudo S, Haraguchi H, Hirai Y, et al
J Virol. 2013 Jan 9.
Abstract
ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz
Levels in South African HIV/AIDS Patients.
Swart M, Ren Y, Smith P, Dandara
C.
Front Genet.
2012;3:236
Abstract |
FULL-TEXT ARTICLE
HIV-1 RNA May Decline More Slowly in Semen than in Blood following Initiation of
Efavirenz-Based Antiretroviral Therapy.
Graham SM, Holte SE, Dragavon JA,
et al
PLoS One. 2012;7(8):e43086.
Paper
Effect of Efavirenz on UDP-Glucuronosyltransferase 1A1, 1A4, 1A6, and
1A9 Activities in Human Liver Microsomes.
Ji HY, Lee H, Lim SR, et
al
Molecules. 2012 Jan
17;17:851-60.
Abstract |
Study on the structure and vibrational spectra of efavirenz conformers
using DFT:
Comparison to experimental data.
Mishra S, Tandon P, Ayala
AP.
Spectrochim Acta A Mol Biomol Spectrosc.
2011 Dec 13.
Abstract |
Non-linear mixed effects modeling of antiretroviral drug response
after administration of lopinavir, atazanavir and efavirenz
containing regimens to treatment-naďve HIV-1 infected patients.
Röshammar D, Simonsson US, Ekvall H,
et al
J Pharmacokinet Pharmacodyn.
2011 Oct 2.
Abstract
Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and
BimEL-dependent mechanism in primary human hepatocytes.
Bumpus NN.
Toxicol Appl Pharmacol. 2011 Sep 19
Abstract
Long-term effect of efavirenz autoinduction on plasma/peripheral blood
mononuclear cell drug exposure
and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV
patients.
Habtewold A, Amogne W, Makonnen E, et al
J Antimicrob Chemother.
2011 Aug 16.
Abstract
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-resistant
Virus is Stimulated by Efavirenz (EFV) During Early Stages of Infection.
Wang J, Zhang G, Bambara RA, Li D,
J Virol.
2011 Aug 10.
Abstract
HIV/AIDS Patients Display Lower Relative Bioavailability of Efavirenz than
Healthy Subjects.
Mukonzo JK, Nanzigu S, Rekić D,
et al
Clin Pharmacokinet. 2011 Aug
1;50(8):
Abstract
The Male Genital Tract Is Not a Pharmacological Sanctuary From Efavirenz.
Avery LB, Bakshi RP, Cao YJ, Hendrix CW.
Clin Pharmacol Ther. 2011
Jun 1.
Abstract
Compromising mitochondrial function with the antiretroviral drug
efavirenz induces cell survival-promoting autophagy.
Apostolova N, Gomez-Sucerquia LJ, Gortat A, et al
Hepatology. 2011 May 29.
Abstract
Effects of nevirapine and efavirenz on human adipocyte differentiation, gene
expression, and release of adipokines
and cytokines.
Díaz-Delfín J, Del Mar Gutiérrez M, Gallego-Escuredo JM, et al
Antiviral Res. 2011 May 17.
Abstract
Study of meta-trajectories of CD4 cells count from taxonomy in
the antiretroviral response of efavirenz-based
regimen with naive symptomatic
patients in Abidjan
Abrogoua DP, Aulagner G, Kablan BJ, Petit C.
Ann Pharm Fr. 2011
Jan;69(1):7-21.
Abstract
Efavirenz concentrations in CSF exceed IC50 for
wild-type HIV.
Best BM, Koopmans PP, Letendre SL, et al
J Antimicrob Chemother.
2010 Nov 23.
Abstract
|
A randomized crossover study to compare efavirenz and
etravirine treatment.
Nguyen A, Calmy A, Delhumeau C, et al
AIDS. 2010 Nov 11.
Abstract |
Differential Effects of Efavirenz and Lopinavir/Ritonavir on Human
Adipocyte Differentiation,Gene Expression and Release of Adipokines and Pro-Inflammatory
Cytokines.
Gallego-Escuredo1 JM, Del Mar Gutierrez M, Diaz-Delfin J, et al
Curr HIV Res.
2010 Oct 1;
Abstract |
Long-Term Efavirenz Autoinduction and Its Effect on
Plasma Exposure in HIV Patients.
Ngaimisi E, Mugusi S, Minzi OM
Clin Pharmacol Ther.
2010 Sep 29.
Abstract |
Efavirenz Plasma Concentrations and Cytochrome 2B6
Polymorphisms
Lindfelt T, O'Brien JA, Song JC, et al
Ann Pharmacother.
2010 Sep 14
Abstract |
Impact of Ritonavir, Atazanavir and their Combination on the CYP3A4
Induction Potential
of Efavirenz in Primary Human Hepatocytes.
Mugundu GM, Hariparsad N, Desai PB.
Drug Metab Lett.
2010 Mar 4.
Abstract |
Efavirenz Binding to HIV-1 Reverse Transcriptase
Monomers and Dimers.
Braz VA,
Holladay LA, Barkley MD.
Biochemistry.
2009 Dec 29
Abstract |
Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with
significantly higher oral bioavailaibility.
Chiappetta DA, Hocht C, Taira C, Sosnik A.
Nanomed. 2010 Jan;5(1):11-23
Abstract |
Efavirenz plasma concentrations did not predict cessation of therapy
due to neuropsychiatric
symptoms in a large randomized trial.
Read TR, Carey D, Mallon P, et al
AIDS.
2009 Sep 21.
Abstract |
Efavirenz: a decade of clinical experience in the treatment of
HIV.
Maggiolo F.
J Antimicrob Chemother. 2009 Sep 18
Abstract |
Non-nucleoside reverse transcriptase inhibitor efavirenz increases
monolayer permeability
of human coronary artery endothelial cells.
Jamaluddin MS, Lin PH, Yao Q, Chen C.
Atherosclerosis.
2009 Jul 23
Abstract |
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6
function.
Iulio JD, Fayet A, Arab-Alameddine M, et al
Pharmacogenet Genomics. 2009 Feb
20
Abstract
|
Efavirenz: a review.
Vrouenraets SM,
Wit FW, van Tongeren J, Lange JM.
Expert Opin Pharmacother. 2007 Apr;8(6):851-71.
Abstract
|
|
Efavirenz Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
